/

Società

Ca

Non verificato

Capsida Biotherapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati

12/05/2026

Mercato del lavoro

Eventi

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

11/06/2025

Igiene alimentare

Salute

Biotecnologia

Farmaceutica

Medicina - Varie

Industria

Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

29/05/2025

Salute

Igiene alimentare

Biotecnologia

Medicina - Varie

Farmaceutica

Industria

Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

14/05/2025

Industria

Salute

Biotecnologia

Medicina - Varie

Scienza

Farmaceutica

Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

12/05/2025

Biotecnologia

Igiene alimentare

Salute

Medicina - Varie

Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

28/04/2025

Web e Social Network

Eventi

Salute

Biotecnologia

Scienza

Sanità

Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)

Fonte

Capsida Biotherapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0